Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo aims to tackle lymphoma that survives CAR-T

NCT ID NCT06760156

Recruiting now Disease control Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 study tests whether the drugs tafasitamab and lenalidomide can shrink or eliminate large B-cell lymphoma that remains after treatment with CAR-T therapy (axicabtagene ciloleucel). About 28 adults with this type of lymphoma will receive the drug combination for up to 12 months. The main goal is to see how many patients achieve a complete response, meaning no cancer is detectable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
tafasitamab and lenalidomide
What this could lead to
If successful, this combination could offer a new treatment option for patients whose lymphoma remains after CAR-T therapy, potentially improving remission rates.
What could go wrong
This is a small, early-phase trial with only 28 participants, so results may not apply broadly. The drugs can cause side effects like low blood counts, infections, or blood clots.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LARGE B-CELL LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.